8-K: Delcath Systems Reports Strong Preliminary Q4 & FY25 Results

Delcath Systems announced robust preliminary Q4 and full-year 2025 financial results, including positive operating cash flow and significant revenue growth for its HEPZATO KIT.

Summary

• Preliminary total revenue for the fourth quarter and full year 2025 is expected to be approximately $20.7 million and $85.2 million, respectively.
• HEPZATO KIT revenue for the fourth quarter and full year 2025 is expected to be approximately $19.0 million and $78.8 million, respectively.
• CHEMOSAT revenue for the fourth quarter and full year 2025 is expected to be approximately $1.7 million and $6.4 million, respectively.
• The company achieved positive operating cash flow for the quarter ended December 31, 2025.
• As of December 31, 2025, the company had approximately $91.0 million of cash and short-term investments and no debt, an increase from $88.9 million as of September 30, 2025.
• 628,572 shares of common stock were repurchased for $6.0 million through December 31, 2025, under the approved $25.0 million Share Buyback Program.
• There are currently 25 active sites utilizing HEPZATO KIT, with approximately 140% growth in HEPZATO procedure volume in 2025 versus 2024.
• Independent investigators presented results from the Phase 2 CHOPIN trial, showing a significant improvement in one-year progression-free survival for CHEMOSAT with ipilimumab and nivolumab in metastatic uveal melanoma versus CHEMOSAT alone.

Sentiment

Score: 8

Explanation: The filing presents strong preliminary financial results, including significant revenue growth, positive operating cash flow, and a healthy cash position with no debt. The substantial increase in HEPZATO procedure volume and positive clinical trial data for combination therapy indicate strong commercial momentum and future growth potential. While the preliminary nature of the results introduces some uncertainty, the overall picture is highly positive for the company's current performance and strategic direction.

Positives

• Strong preliminary total revenue for Q4 2025 ($20.7 million) and full year 2025 ($85.2 million) indicates robust commercial performance.
• Significant growth in HEPZATO KIT revenue, reaching $78.8 million for the full year, highlights successful market penetration.
• Achieved positive operating cash flow for Q4 2025, demonstrating improved financial health and operational efficiency.
• Robust cash and short-term investments of $91.0 million with no outstanding debt provides a strong financial position for future investments.
• Active share buyback program, repurchasing 628,572 shares for $6.0 million, signals management's confidence in the company's valuation.
• Approximately 140% growth in HEPZATO procedure volume in 2025 compared to 2024 indicates strong adoption and demand for the product.
• Expansion to 25 active HEPZATO KIT sites demonstrates increasing access and utilization of the therapy.
• Positive Phase 2 CHOPIN trial results show significant improvement in one-year progression-free survival for CHEMOSAT combined with ipilimumab and nivolumab, validating potential synergy with checkpoint inhibitors.
• HEPZATO KIT is the first and only FDA-approved whole-liver directed therapy for metastatic uveal melanoma (mUM).
• The company has IND approval for Phase 2 trials in metastatic colorectal cancer (mCRC) and metastatic breast cancer (mBC), indicating pipeline expansion and future growth opportunities.

Negatives

• Revenue reduction due to 340B pricing, which began July 1, 2025, and seasonality of new patient starts, impacted revenue progression.
• The reported financial results are preliminary and unaudited, subject to potential audit adjustments and other developments that may cause actual results to vary.

Risks

• Uncertainties relating to the company’s commercialization plans and its ability to successfully commercialize the HEPZATO KIT.
• Uncertainties regarding contributions to adjusted EBITDA.
• Uncertainties relating to the company's successful management of the HEPZATO KIT supply chain, including securing adequate supply of critical components.
• Uncertainties regarding successful FDA inspections of the facilities of the company and its third-party suppliers/manufacturers.
• Uncertainties relating to the company's successful implementation and management of the HEPZATO KIT Risk Evaluation and Mitigation Strategy (REMS).
• Uncertainties regarding the potential benefits of the HEPZATO KIT as a treatment for patients with primary and metastatic disease in the liver.
• Uncertainties regarding the company's ability to obtain reimbursement for the HEPZATO KIT.
• Uncertainties regarding the company's ability to successfully enter into any necessary purchase and sale agreements with users of the HEPZATO KIT.
• Uncertainties relating to the timing and results of research and development projects and clinical trials.
• Uncertainties regarding the company's ability to obtain financial and other resources for any research, development, clinical trials, and commercialization activities.
• New risk factors and uncertainties may emerge from time to time, and it is not possible to predict all.

Future Outlook

The company plans to continue driving increased adoption and utilization of HEPZATO KIT in 2026 by raising awareness of the CHOPIN study findings among treating physicians. Its strong financial position will enable investment in both commercial expansion and the initiation of additional clinical programs in 2026, including ongoing Phase 2 trials for metastatic colorectal cancer (mCRC) and metastatic breast cancer (mBC).

Management Comments

• "In 2026 we will continue to drive increased adoption and utilization of HEPZATO by raising awareness among treating physicians of the CHOPIN study findings."
• "Our strong financial position enables us to invest in both commercial expansion and the initiation of additional clinical programs in 2026."

Industry Context

Delcath Systems operates in the interventional oncology space, focusing on liver-directed therapies for primary and metastatic liver cancers, a field with high unmet medical need. Its HEPZATO KIT and CHEMOSAT products offer a unique percutaneous hepatic perfusion (PHP) system designed to deliver high-dose chemotherapy directly to the liver while minimizing systemic exposure. This approach addresses the limitations of traditional liver-directed therapies like TACE and SIRT, which may not be suitable for diffuse disease or whole-liver treatment. The company is expanding beyond its initial metastatic uveal melanoma (mUM) indication into metastatic colorectal cancer (mCRC) and metastatic breast cancer (mBC), targeting a broader market with significant incidence. The positive CHOPIN trial results, showing synergy with checkpoint inhibitors, position Delcath favorably in the evolving landscape of combination therapies for advanced cancers.

Comparison to Industry Standards

• HEPZATO KIT's FOCUS pivotal trial for metastatic uveal melanoma (mUM) demonstrated an Overall Response Rate (ORR) of 36.3%, a Median Progression-Free Survival (PFS) of 9.0 months, and a Median Overall Survival (OS) of 20.53 months.
• These results compare favorably to a meta-analysis of systemic and liver-directed therapies (Khoja et al. 2019) for mUM, which reported a median OS of 10.2 months and PFS of 3.3 months.
• Another meta-analysis (Rantala et al. 2019) showed a median OS of 12.84 months for mUM treatments.
• Systemic competitors like ipilimumab plus nivolumab (Piulats et al. 2021) for mUM showed a median OS of 12.7 months and PFS of 3.0 months.
• Tebentafusp (Nathan et al. 2021) for treatment-naive mUM patients showed an OS of 21.7 months (73% 1-year OS) and PFS of 3.3 months, with a control arm OS of 16 months and PFS of 2.9 months. HEPZATO's 20.53 months OS is comparable to tebentafusp, but its PFS of 9.0 months is significantly higher than tebentafusp's 3.3 months.
• The Phase 2 CHOPIN trial demonstrated a significant improvement in one-year progression-free survival for CHEMOSAT with ipilimumab and nivolumab (54.7%) versus CHEMOSAT alone (15.8%), and an ORR of 76.3% vs 39.5%. This combination also showed a median PFS of 12.8 months and median OS of 23.1 months, outperforming historical benchmarks for checkpoint combination in mUM (ORR 15%, PFS 3.8 months, median OS 16 months).
• Traditional liver-directed therapies such as Trans Arterial Chemo Embolization (TACE) and Selective Internal Radiation Therapy (SIRT) have limitations for diffuse disease and whole-liver treatment, and are not approved for mUM, lacking substantial high-quality data to support usage in this indication.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, share buyback program, and potential for future growth from pipeline expansion and increased product adoption.
• Patients: Positive impact due to the availability of an FDA-approved liver-directed therapy for mUM and promising clinical trial results for combination therapies, potentially leading to improved outcomes for liver cancer patients.
• Employees: Positive impact from company growth and expansion, potentially leading to job security and opportunities.
• Healthcare Providers: Increased awareness and adoption of HEPZATO KIT and CHEMOSAT, providing more treatment options for liver cancer patients.

Next Steps

• Provide final financial results for the fourth quarter and full year 2025 during the annual financial results release and business update call.
• Continue to drive increased adoption and utilization of HEPZATO KIT in 2026.
• Raise awareness among treating physicians of the CHOPIN study findings.
• Invest in commercial expansion in 2026.
• Initiate additional clinical programs in 2026, including ongoing Phase 2 trials for metastatic colorectal cancer (mCRC) and metastatic breast cancer (mBC).

Key Dates

Recommendation

The filing indicates robust preliminary financial performance with significant revenue growth for HEPZATO KIT, positive operating cash flow, and a strong balance sheet with no debt. The 140% increase in procedure volume and expansion of active treatment centers demonstrate strong market adoption. Furthermore, the positive Phase 2 CHOPIN trial results, showing enhanced efficacy with combination therapy, and the ongoing expansion into mCRC and mBC indications, suggest substantial future growth potential and a broadening market opportunity. The share buyback program also signals management's confidence. These factors collectively point to a company with strong fundamentals and significant upside.

Keywords

Interventional Oncology, Liver Cancer, Metastatic Uveal Melanoma, mUM, HEPZATO KIT, CHEMOSAT, Melphalan, Hepatic Delivery System, PHP, Percutaneous Hepatic Perfusion, Oncology, FDA Approved, Clinical Trials, Financial Results, DCTH, NASDAQ